TY - JOUR
T1 - The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves’ ophthalmopathy
AU - Khazaei, Hadi
AU - Khazaei, Danesh
AU - Verma, Rohan
AU - Ng, John
AU - Wilmarth, Phillip
AU - David, Larry L.
AU - Rosenbaum, James (Jim)
N1 - Funding Information:
JTR consults for Horizon, Abbvie, Novartis, Roche, Eyevensys, Santen, Affibody, Kyverna and Covrus. JTR receives research support from Pfizer and Horizon and royalties from UpToDate.
Funding Information:
JTR receives support from the Grandmaison Fund for Autoimmunity Research, the Stan and Madelle Rosenfeld Family Trust, the William and Mary Bauman Family Foundation, Research to Prevent Blindness , United States.
Funding Information:
This work was supported by NIH grants EY020249 and P30 EY010572 .
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/12
Y1 - 2021/12
N2 - Background: Orbital compartments harbor a variety of tissues that can be independently targeted in a plethora of disorders resulting in sight-threatening risks. Orbital inflammatory disorders (OID) including Graves’ ophthalmopathy, sarcoidosis, IgG4 disease, granulomatosis with polyangiitis, and nonspecific orbital inflammation constitute an important cause of pain, diplopia and vision loss. Physical examination, laboratory tests, imaging, and even biopsy are not always adequate to classify orbital inflammation which is frequently deemed “nonspecific”. Tear sampling and testing provide a potential “window” to the orbital disease process through a non-invasive technique that allows longitudinal sampling as the disease evolves. Using PubMed/Medline, we identified potentially relevant articles on tear proteomics published in the English language between 1988 and 2021. Of 303 citations obtained, 225 contained empirical data on tear proteins, including 33 publications on inflammatory conditions, 15 in glaucoma, 15 in thyroid eye disease, 1 in sarcoidosis (75) and 2 in uveitis (77,78). Review articles were used to identify an additional 56 relevant articles through citation search. In this review, we provide a short introduction to the potential use of tears as a diagnostic fluid and tool to investigate the mechanism of ocular diseases. A general review of previous tear proteomics studies is also provided, with a focus on Graves' ophthalmopathy (GO), and a discussion of unmet needs in the diagnosis and treatment of orbital inflammatory disease (OID). The review concludes by pointing out current limitations of mass spectrometric analysis of tear proteins and summarizes future needs in the field.
AB - Background: Orbital compartments harbor a variety of tissues that can be independently targeted in a plethora of disorders resulting in sight-threatening risks. Orbital inflammatory disorders (OID) including Graves’ ophthalmopathy, sarcoidosis, IgG4 disease, granulomatosis with polyangiitis, and nonspecific orbital inflammation constitute an important cause of pain, diplopia and vision loss. Physical examination, laboratory tests, imaging, and even biopsy are not always adequate to classify orbital inflammation which is frequently deemed “nonspecific”. Tear sampling and testing provide a potential “window” to the orbital disease process through a non-invasive technique that allows longitudinal sampling as the disease evolves. Using PubMed/Medline, we identified potentially relevant articles on tear proteomics published in the English language between 1988 and 2021. Of 303 citations obtained, 225 contained empirical data on tear proteins, including 33 publications on inflammatory conditions, 15 in glaucoma, 15 in thyroid eye disease, 1 in sarcoidosis (75) and 2 in uveitis (77,78). Review articles were used to identify an additional 56 relevant articles through citation search. In this review, we provide a short introduction to the potential use of tears as a diagnostic fluid and tool to investigate the mechanism of ocular diseases. A general review of previous tear proteomics studies is also provided, with a focus on Graves' ophthalmopathy (GO), and a discussion of unmet needs in the diagnosis and treatment of orbital inflammatory disease (OID). The review concludes by pointing out current limitations of mass spectrometric analysis of tear proteins and summarizes future needs in the field.
KW - Eye Proteins/analysis
KW - Eye diseases/diagnosis/metabolism
KW - Graves' ophthalmopathy
KW - Mesh
KW - Molecular diagnostic techniques/methods
KW - Orbital inflammatory diseases/diagnosis/metabolism
KW - Proteome/metabolism
KW - Proteomics/methods
KW - Tear Biomarkers/metabolism
KW - Tear proteomics
KW - Tears/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85118946532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118946532&partnerID=8YFLogxK
U2 - 10.1016/j.exer.2021.108813
DO - 10.1016/j.exer.2021.108813
M3 - Review article
C2 - 34742692
AN - SCOPUS:85118946532
SN - 0014-4835
VL - 213
JO - Experimental Eye Research
JF - Experimental Eye Research
M1 - 108813
ER -